-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although endocrine therapy is the main treatment for hormone receptor positive (HR+)/HER2-metastatic breast cancer , patients who are at risk of visceral crisis or have insufficient sensitivity to endocrine therapy require first-line chemotherapy
.
Hormonal maintenance therapy is usually given when chemotherapy is stopped
Breast cancer
Recruited patients with ER+/HER2-metastatic breast cancer who had achieved partial remission or complete remission after first-line chemotherapy and were randomly divided into two groups and received everolimus combined with AI (exemestane or letrozole).
Or Anastrozole) or AI therapy alone
.
The primary endpoint is progression-free survival (PFS)
PFS and OS of the two groups
PFS and OS of the two groupsIn total, 110 patients were randomly divided into two groups: 52 in the everolimus + AI group and 58 in the AI group
.
The median PFS of the everolimus+AI group and the AI group were 11.
The median PFS of everolimus + AI group and AI group were 11.
Everolimus combined with AI did not significantly improve the prognosis of patients with metastatic breast cancer after first-line chemotherapy compared with AI alone
Original source:
Guarneri Valentina,Giorgi Carlo Alberto,Cinieri Saverio et al.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial in this message